Importantly, the well-established safety profile of SVHRSP, as confirmed in regulatory-approved toxicology studies, allows us to conclude that its anti-colitis efficacy at the therapeutic dose of 400 μg/kg/day is mediated by a specific activation of the α7nAChR–JAK2/STAT3 pathway, rather than by nonspecific immunosuppression or systemic toxicity. Here, CHRNA7 is linked to colitis.